Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
If the state starts prosecuting DNA crime they’ll just swab people they don’t need a private firm barely anyone’s used to collapse.
Dodgy American insurance firms could try and get their hands on the data no doubt, but Regeneron has to abide by the same data protection rules as 23andme.